Reaction profile
The FDA adverse-event record for abnormal pancreatic specific lipase (pli)
11 FDA adverse-event reports reference abnormal pancreatic specific lipase (pli) (VeDDRA 93049). See the species, breeds, and drugs most associated with it below.
- 11
- reports citing this reaction
- 27.3%
- death-coded share
- Dog
- most-affected species
- Milbemycin Oxime + Spinosad
- most-associated drug
Species Most Affected
Breeds Most Affected
Associated Drugs
ABNORMAL PANCREATIC SPECIFIC LIPASE (PLI) Reaction Insights
11 reports name ABNORMAL PANCREATIC SPECIFIC LIPASE (PLI); 3 recorded a death outcome (27.3% of reported events, not a population-level mortality rate). VeDDRA code: 93049.
By species: Dog (7 reports), Cat (4 reports). By breed: Domestic Shorthair (2), Sheepdog - Shetland (1), Shepherd Dog - Australian (1).
Most co-reported drugs: Milbemycin Oxime + Spinosad (2 reports), Cyclosporine (2 reports), Semintra Telmisartan 4 Mg/Ml (2 reports), Nitenpyram (1 reports).
Read these counts as reporting volume, not risk: per our methodology, co-reporting reflects temporal association captured in voluntary submissions, not proof that a drug caused this reaction. A widely-prescribed drug will rack up more raw co-reports at an identical true rate than a rarely-used one, so compare within similar-exposure products.
Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025
Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.